KINOMED partnership to speed up kinase drug discovery
Will offer 3D structures of kinases with novel lead compounds
The KINOMED Partnership, funded by the EU’s Eurostars programme, will provide an integrated package of services for protein kinase inhibitor discovery and development.
The partnership between Denmark’s KinaseDetect, Sweden’s SARomics and the UK’s IOTA will offer kinase production, assay development, crystal structure determination, fragment library construction, hit finding and optimisation, in silico screening, biochemical and biophysical screening, structure- and ligand-based drug design and medicinal chemistry services.
Olaf-Georg Issinger, director of KinaseDetect, said: ‘Structure-based drug design in combination with fragment-based lead discovery is a powerful combination in modern drug discovery. We are collaborating with IOTA Pharmaceuticals and SARomics Biostructures in developing a service platform to provide the pharmaceutical industry with off-the-shelf three-dimensional structures of kinases and their complexes with novel lead compounds.’
